RxDoctor Payments Data

Chinyere Awa, MD

Family Medicine · Houston, TXNPI 1669415279

Payments from drug & device makers

$200,330in general payments, 2019–2025

Across 39 payments — averaging $5136.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sanofi US Services Inc.$82K
  • Eli Lilly$65K
  • Sanofi Pasteur Inc.$52K
  • Lilly USA, LLC$148
  • Fresenius Kabi USA, LLC$78
  • Abbott$69
  • plus $208 from 8 others

What the payments were for

  • Food & beverage$504100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$200,330 in reported general payments places this provider in the 95th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$17,060
Medicare patients
64
Services billed
249

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab13$170,629
OzempicSemaglutide45$58,225
JardianceEmpagliflozin47$55,238
EliquisApixaban38$50,442
TrulicityDulaglutide15$35,638
MyrbetriqMirabegron20$26,203
JanuviaSitagliptin Phosphate19$24,881
VemlidyTenofovir Alafenamide13$21,727
Trelegy ElliptaFluticasone/Umeclidin/Vilanter23$17,349
MounjaroTirzepatide15$16,044
FarxigaDapagliflozin Propanediol14$15,893
XareltoRivaroxaban16$14,405
Spiriva HandihalerTiotropium Bromide15$10,770
PremarinEstrogens, Conjugated24$7,955
Advair HfaFluticasone Propion/Salmeterol13$4,842

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Premarin$32$58,39762 claims
Novo NordiskOzempic$36$58,22545 claims
Lilly USA, LLCTrulicity, Mounjaro$148$51,68230 claims
GileadVemlidy$57$21,72713 claims
GSKTrelegy Ellipta$21$17,34923 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Houston

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →